Risks of hydroxychloroquine use for COVID-19 prophylaxis - 19/06/20
Doi : 10.1016/j.jaad.2020.04.111
Muskaan Sachdeva, BHSc a, ⁎ 
, Monica Shah, BSc a, Michael Ziv, MD b, Eyal Leshem, MD c, d, Roni P. Dodiuk-Gad, MD b, d, e, f
, Monica Shah, BSc a, Michael Ziv, MD b, Eyal Leshem, MD c, d, Roni P. Dodiuk-Gad, MD b, d, e, f a Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
b Dermatology Department, Emek Medical Center, Afula, Israel
c Institute for Travel and Tropical Medicine, Sheba Medical Center, Ramat Gan, Israel
d School of Medicine, Tel Aviv University, Tel Aviv, Israel
e Bruce Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel
f Department of Medicine, University of Toronto, Toronto, Ontario, Canada
∗Correspondence to: Muskaan Sachdeva, BHSc, Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, CanadaFaculty of MedicineUniversity of Toronto1 King's College CircleTorontoONM5S 1A8Canada
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 1
P. e73-e74 - juillet 2020 Retour au numéro
Article précédent
- Telemedicine for inpatient dermatology consultations in response to the COVID-19 pandemic
- John Trinidad, Daniela Kroshinsky, Benjamin H. Kaffenberger, Nathan W. Rojek
- Response to: “Risks of hydroxychloroquine use for COVID-19 prophylaxis”
- Jane M. Grant-Kels
Bienvenue sur EM-consulte, la référence des professionnels de santé.